Poly ICLC ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
34Neurofibromatosis1

34. Neurofibromatosis


Clinical trials : 137 Drugs : 213 - (DrugBank : 76) / Drug target genes : 87 - Drug target pathways : 200
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04544007
(ClinicalTrials.gov)
December 15, 20212/9/2020A Phase II Trial of Poly-ICLC for Low-Grade GliomasA Phase II Trial of Poly-ICLC for Progressive, Previously Treated Low-Grade Gliomas in Children and Young Adults With Neurofibromatosis Type 1NF1;Low-grade GliomaDrug: Poly ICLCUniversity of Alabama at BirminghamChildren's Healthcare of Atlanta;Children's Hospital Los AngelesNot yet recruitingN/A22 YearsAll20Phase 2United States